Coronavirus Scientific Advisory Board

Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee

Retrieved on: 
Thursday, October 19, 2023
Mayo Clinic Alix School of Medicine, Exosome, NRX, Coronavirus Scientific Advisory Board, Growth, Medicine, DSM-IV codes, Advisory Committee, FSE, Patient, Pharmaceutical industry

Professor Dagi’s decision to join the Scientific Advisory Board stems from his profound belief in the regenerative potential of exosomes for neurological diseases.

Key Points: 
  • Professor Dagi’s decision to join the Scientific Advisory Board stems from his profound belief in the regenerative potential of exosomes for neurological diseases.
  • According to Professor Dagi, “The problem of neural regeneration and recovery from neurological injury is one of the most difficult and pressing unresolved problems in medicine.
  • Our heartfelt condolences go out to families with lost or missing loved ones.
  • We extend sincere appreciation to our investors and partners for their continued warm support.

mbiomics Appoints Seasoned Microbiome Expert Christopher Weidenmaier as Chief Scientific Officer

Retrieved on: 
Tuesday, October 24, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Principal, Host, Harvard Medical School, CSO, Therapy, Conditional sentence, Doctor of Philosophy, Directorate of Research and Civil Affairs, Division, The German, University, Culture, Infection, Hospital, Coronavirus Scientific Advisory Board, Antibiotics, Microbiology, Hygiene

mbiomics today announced the appointment of Christopher Weidenmaier, PhD, as Chief Scientific Officer (CSO).

Key Points: 
  • mbiomics today announced the appointment of Christopher Weidenmaier, PhD, as Chief Scientific Officer (CSO).
  • Dr. Weidenmaier will contribute nearly 20 years of experience in the microbiome and infectious diseases fields and lead the company’s discovery and development efforts as they establish a pipeline of complex microbiome ecosystems product candidates.
  • Over the course of his career, Dr. Weidenmaier has successfully developed and led R&D efforts for next-generation microbiome products.
  • The appointment will strategically expand the mbiomics’ leadership team on its mission to harness the full potential of the microbiome to restore health and overcome disease.

3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, CAR, PD-L1, UCSF, CSO, IND, Autoimmunity, Therapy, Culture, TCR, Lightspeed Venture Partners, Investigational New Drug, University of California, CTA, Acquisition, Immunity, Research, Journal of Experimental Medicine, Harvard University, Inflammation, Multimedia, R, Journal, Cancer immunology, Cell, Nature Communications, Immune system, Amgen, Drug discovery, Cancer, Microbiology, Canadian Aviation Regulations, Medical research, Immunotherapy, University, Roche, Sanofi, Genentech, Safety, Patient, Doctor of Philosophy, Coronavirus Scientific Advisory Board, Management, Vaccine, Pharmaceutical industry, Science

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 /PRNewswire/ -- 3T Biosciences ("3T"), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Bryan Irving, Ph.D., as chief scientific officer (CSO). In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.

Key Points: 
  • In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.
  • His work has focused primarily on exploring ways to modulate T-cell activity for therapeutic benefit in both oncology and autoimmune settings.
  • "3T shares my passion for innovation and has a culture of rigor and dedication to advancing novel therapies.
  • 3T Biosciences is an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response-guided target discovery approach.

Res Nova Biologics Recruits Abortion Pill Reversal Founder to Scientific Advisory Board

Retrieved on: 
Tuesday, October 17, 2023
Science, Women, Biotechnology, Research, Pharmaceutical, Oncology, Health, Consumer, Neoplasm, Multimedia, Progesterone, UC, Reproductive medicine, Biology, Breast cancer, ST, Coronavirus Scientific Advisory Board, Pregnancy, Immunotherapy, Santa Monica, California, Growth, Translation, University of California, Davis, TSOI, Pharmaceutical industry, Birth control, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20231017959162/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231017959162/en/
    Dr. Delgado is an expert in the biology of pregnancy and the abortion pill, being the founder of “Abortion Pill Reversal” and having been the first to publish in the peer-reviewed literature successful reversal of mifepristone administration using progesterone treatment1.
  • Res Nova is developing FloraStilbene™, a proprietary formulation of RU-486 and pterostilbene which has been shown to overcome tumor associated immune suppression2 and increases responsiveness to chemotherapy and immunotherapy3.
  • “The similarities between pregnancy and oncology, including angiogenesis, immune modulation, and rapid growth are striking,” said Dr. George Delgado.
  • “In my opinion the concept of leveraging the effects of the abortion pill in life-saving as opposed to a life-taking scenario is extremely exciting.

Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer

Retrieved on: 
Tuesday, October 17, 2023
Health, Technology, Health Technology, Nanotechnology, Artificial Intelligence, Biotechnology, Vitae, Cyrus, IPD, Scripps Research, Drug development, Machine learning, Bristol Myers Squibb, Berkeley, Coronavirus Scientific Advisory Board, University, Artificial intelligence, Therapy, Affymetrix, Protein, Molecular biology, Cell biology, Drug discovery, ARCH Venture Partners, Harmon, Pharmaceutical industry, Vilya, Muller's morphs

VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.

Key Points: 
  • VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.
  • “I am very excited to join the phenomenal team at Vilya developing new macrocycle drugs,” said Harmon.
  • Previously, Harmon co-founded and served as CEO of Olema Oncology, a company focused on women’s cancers, before transitioning to the role of Chief Research Officer.
  • Harmon joins Katerina Leftheris, Ph.D., Vilya’s Chief Scientific Officer on the company’s leadership team.

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)

Retrieved on: 
Friday, October 13, 2023
ALS, Positron emission tomography, Nuclear medicine, Coronavirus Scientific Advisory Board, Mass, PET, Hospital, Disease, Expanded access, Patient, FDA, Special access program, Microglia, Neurology, Harvard Medical School, Assistant, Multiple sclerosis, DSM-IV codes, Microsoft Access, EAP, Medical imaging, Brigham

Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis, or ALS.

Key Points: 
  • Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis, or ALS.
  • When combined with my assessment of the first two Expanded Access patients at six-months, five of the six suggested a reduction in qualitative microglial PET signal.
  • An example of this can be seen in the graphic below, titled, “Figure 1”, showing the deactivation of this signal in patient EA6.
  • This is promising from an imaging standpoint, and further studies are needed to confirm these findings using additional quantitative approaches."

AstriVax Strengthens Leadership Team by Welcoming Chief Development Officer (CDO) Dr. Mathieu Peeters and Chief Financial Officer (CFO) Barbara Freitag

Retrieved on: 
Tuesday, October 10, 2023
Vaccine, Knowledge, MBA, COPD, PwC, HSV, Coronavirus Scientific Advisory Board, R, Ernst & Young, CDO, RSV, CFO, Pharmaceutical industry, Sutro Biopharma, Thrombogenicity

Dr. Mathieu Peeters brings an extensive clinical vaccine development track record from his senior roles at GSK Vaccines.

Key Points: 
  • Dr. Mathieu Peeters brings an extensive clinical vaccine development track record from his senior roles at GSK Vaccines.
  • Barbara Freitag joins AstriVax as an accomplished CFO in the biotech sector.
  • Leuven, Belgium, October 10, 2023 – AstriVax is pleased to announce that Dr. Mathieu Peeters and Barbara Freitag have joined the company’s leadership team as Chief Development Officer and Chief Financial Officer, respectively.
  • With AstriVax soon entering into clinical stage, I am excited that Mathieu has joined us as CDO to steer our clinical vaccine development.

EQS-News: AATec Medical GmbH: AATec Medical Announces Creation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 17, 2023
Health, GS, Georgetown University Medical Center, Viral, International Society, University Medical Center, Technical University of Munich, Leibniz-Institute of Virology, Institute of technology, Coronavirus Scientific Advisory Board, EMA, Asthma, Aerosol, Acute respiratory distress syndrome, Nature Communications, AAT, Research, ISAM, Pharmaceutical industry, Vaccine, Virology, Inam-ul-Haq (diplomat), Medicine

Leading scientific and clinical experts, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch, join the newly established Scientific Advisory Board

Key Points: 
  • Leading scientific and clinical experts, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch, join the newly established Scientific Advisory Board
    Munich, Germany – 10 October 2023 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), today announced the creation of a Scientific Advisory Board.
  • Dr. Rüdiger Jankowsky, CEO commented: "We are honored to have such esteemed scientific experts joining AATec as advisors.
  • Our Scientific Advisory Board is composed of pioneers in the fields of respiratory diseases, viral infections, and aerosolized drugs.
  • The creation of the Scientific Advisory Board underscores AATec's commitment to unlocking the therapeutic potential of AAT, a human serine protease inhibitor with broad anti-inflammatory and antiviral effects to treat respiratory inflammatory diseases.

Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board

Retrieved on: 
Thursday, October 5, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Aurora, Histology, Chinese University of Hong Kong, Multimedia, Science, Lung cancer, Biomarker, Chinese, University, Cedars-Sinai Medical Center, CLDN1, Abstract, Lung transplantation, The New England Journal of Medicine, AACR, Anesthesiology, Clinical Oncology, Clarivate, Long Island Jewish Medical Center, Book, Coronavirus Scientific Advisory Board, IPF, Respiratory therapist, University of the Witwatersrand School of Chemical and Metallurgical Engineering, Food and Drug Administration, Lung, US Food Sovereignty Alliance, Medical director, Patient, Idiopathic pulmonary fibrosis, AstraZeneca, ESMO, Therapy, Article, Publication, Long Island, ASCO, Pulmonary hypertension, CSCO, Research, Inova Fairfax Hospital, Pharmaceutical industry, Medical device, Vaccine

Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.

Key Points: 
  • Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20231005193827/en/
    Lung experts Prof. Steven Nathan and Prof. Tony Mok join Alentis Therapeutics' Scientific Advisory Board.
  • (Photo: Alentis Therapeutics)
    “Tony and Steven have exceptional expertise in lung cancer and lung fibrosis, respectively, which will be of great value to our Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis.
  • Prof. Steven Nathan is the Medical Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and is a Professor at the University of Virginia.

HumanN is the #1 Cardiologist Recommended Beet Brand for Cardiovascular Health Support

Retrieved on: 
Thursday, October 12, 2023
Health, Nitric oxide, Doctor of Philosophy, Cardiology, Medicine, MD, Science and technology in Asia, Coronavirus Scientific Advisory Board, Trust, Patient, Functional food, AHA, Research, Pennsylvania State University, Dietary supplement, Humann

AUSTIN, Texas, Oct. 12, 2023 /PRNewswire/ -- Humann, an industry leader in functional food and nutritional supplements for human health is pleased to announce its latest recognition for the SuperBeets® product line as the #1 Cardiologist Recommended Beet Brand for Cardiovascular Health Support.

Key Points: 
  • AUSTIN, Texas, Oct. 12, 2023 /PRNewswire/ -- Humann, an industry leader in functional food and nutritional supplements for human health is pleased to announce its latest recognition for the SuperBeets® product line as the #1 Cardiologist Recommended Beet Brand for Cardiovascular Health Support.
  • According to a leading independent survey conducted by IQVIA™ ProVoice Survey this year, SuperBeets® by Humann is the #1 cardiologist recommended beet brand for cardiovascular health support.
  • This comes in addition to SuperBeets® recent recognition as the #1 doctor recommended beet brand for heart health support and the #1 pharmacist recommended beet brand for heart health support.
  • My research and interests are aligned with Humann, to change people's lives, starting with improving cardiovascular health."